Skip to main content

Table 4 Safety profile during week 16 (placebo-controlled period) and the entire safety reporting period

From: Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Variable Through week 16 (placebo-controlled period)a Entire safety-data period
Secukinumab IV-300 mg (N = 76) Secukinumab IV-150 mg (N = 74) Placebo (N = 75) Any secukinumab 300 mg (N = 113) Any secukinumab 150 mg (N = 110) Any secukinumab (N = 223)
Exposure to study treatment, days, mean ± SD 112.9 ± 14.2 117.4 ± 13.1 112.2 ± 19.4 410.7 ± 108.9 425.9 ± 92.4 418.2 ± 101.1
  Number of patients (%) Number of patients (incidence rate per 100 patient years)
Any AE 34 (44.7) 34 (45.9) 33 (44.0) 83 (152.7) 90 (179.2) 173 (165.4)
Serious AE 1 (1.3) 0 (0.0) 1 (1.3) 6 (4.8) 6 (4.8) 12 (4.8)
Discontinued due to AEs 0 (0.0) 0 (0.0) 0 (0.0) 4 (3.5) 4 (3.6) 8 (3.6)
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Common AEsa
 Nasopharyngitis 3 (3.9) 6 (8.1) 2 (2.7) 16 (13.7) 22 (19.6) 38 (16.6)
 Diarrhea 3 (3.9) 5 (6.8) 0 (0.0) 8 (6.6) 9 (7.5) 17 (7.0)
 Headache 3 (3.9) 5 (6.8) 5 (6.7) 11 (9.1) 12 (10.1) 23 (9.6)
 Cough 3 (3.9) 3 (4.1) 1 (1.3) 5 (4.1) 3 (2.4) 8 (3.2)
 Pharyngitis 3 (3.9) 1 (1.4) 1 (1.3) 4 (3.2) 3 (2.4) 7 (2.8)
 Ear infection 3 (3.9) 0 (0.0) 0 (0.0) 3 (2.4) 0 3 (1.2)
 Urinary tract infection 3 (3.9) 0 (0.0) 3 (4.0) 6 (4.9) 3 (2.4) 9 (3..6)
AEs of special interest
Candida infection 1 (1.4) 1 (1.3) 0 (0.0) 2 (1.8) 2 (1.8) 4 (1.8)
 Malignant tumor 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9) 1 (0.9) 2 (0.9)
Neutropenia       
 Grade 3 0 (0.0) 1 (1.4) 0 (0.0) 1 (0.9) 1 (0.9) 2 (0.9)
 Grade 4 0 (0.0) 2 (2.7) 0 (0.0) 0 (0.0) 2 (1.8) 2 (0.9)
  1. The entire safety reporting period includes all safety data up to the date cutoff of the last patient’s week 52 clinic visit. One patient was excluded from placebo group as no treatment was given after randomization. In the analysis of the entire study period, the secukinumab groups include any patients who received the stated dose of secukinumab, including those who were randomly assigned to the placebo group at baseline and who underwent a second randomization to active treatment at week 16
  2. N number of patients, AE adverse event, SD standard deviation
  3. aAEs with frequency ≥3% in either of the two secukinumab groups during the 16-week placebo-controlled period